International Pharmaceutical Transparency Act of 2019

Bill: 116-hr-5381
Sponsor: full_name: Rep. DesJarlais, Scott [R-TN-4]
Introduced: 2019-12-10
Policy area: Health
Subjects: Consumer affairs

Drug safety, medical device, and laboratory regulation

Prescription drugs
Latest action: action_date: 2019-12-11
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2019-12-10
action_desc: Introduced in House
text: <p><b>International Pharmaceutical Transparency Act of 2019</b></p> <p>This bill prohibits the sale of a drug if its label fails to list the country of origin of each of the drug's active ingredients.</p>

tv_txt: I 116th CONGRESS 1st Session H. R. 5381 IN THE HOUSE OF REPRESENTATIVES December 10, 2019 Mr. DesJarlais introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug to list the country of origin of each of the drug’s active ingredients.

1. Short title This Act may be cited as the International Pharmaceutical Transparency Act of 2019 . 2. Country-of-origin labeling for active ingredients in drugs (a) Misbranding Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (ee) If it is a drug and its label fails to list the country of origin of each of its active ingredients. . (b) Applicability Section 502(ee) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies beginning on the day that is 6 months after the date of enactment of this Act.